Ecron Acunova CRO Expands its Clinical Research Center for Drug Development
Ecron Acunov announced expansion of their Mangalore Clinical Pharmacology Unit to a 80 bed facility. The Research Center was dedicated by Dr. Ramdas M Pai, Chancellor, Manipal University.
This expansion caters to the growing needs of its global clients in Pharmaco-Kinetic and Pharmaco Dynamic studies. This takes total bed capacity to 176 units in research centers at Mangalore, Manipal, and Bangalore. Drug research involves analyzing the activity of the drug in plasma using spectroscopy. Highly sophisticated spectrometers have been added. Speaking on the occasion Dr. Ramdas Pai said, "I commend the safe conduct of studies for Indian and global companies, leveraging the scientific and clinical talent of India. It is heartening to note that studies conducted at the center, got US FDA approval, leading to launch of drugs for treatment of HIV, cancer etc."
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
